Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00016016 · ClinicalTrials.gov registry record · Phase 1
Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT00016016: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00016016 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 53 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (12% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00016016, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
Phase II trial to study the effectiveness of combining flavopiridol and cytarabine with mitoxantrone in treating patients who have acute leukemia. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
Interventions
- OTHER pharmacological study
- DRUG cytarabine
- DRUG alvocidib
- DRUG mitoxantrone hydrochloride
- OTHER laboratory procedure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2001-02 |
| Phase | Phase 1 |
What the finished NCT00016016 record still lists
NCT00016016 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (12% lower).
The record links to 0 conditions, and to 5 interventions - of which pharmacological study is the first listed.
NCT00016016 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00016016 about?
NCT00016016 is a clinical study titled "Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia". Phase II trial to study the effectiveness of combining flavopiridol and cytarabine with mitoxantrone in treating patients who have acute leukemia. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill m...
What is the current status of trial NCT00016016?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2001-02.
What interventions are being tested in trial NCT00016016?
The interventions under investigation include: pharmacological study (OTHER), cytarabine (DRUG), alvocidib (DRUG), mitoxantrone hydrochloride (DRUG), laboratory procedure (OTHER).
Who is sponsoring clinical trial NCT00016016?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00016016's enrollment target sits among peer trials
53 948th of 2000 higher than 1,045 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia